Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
NCT04551898
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
181
Enrollment
INDUSTRY
Sponsor class
Conditions
Covid19
Interventions
DRUG:
BGB-DXP593
DRUG:
Placebo
Sponsor
BeiGene